Login to Your Account


Abbvie continues to impress investors after its 2013 spinout from Abbott

By Peter Winter
BioWorld Insight Editor

Thursday, January 16, 2014
SAN FRANCISCO – It has been exactly one year since Abbott spun out its research-based pharmaceuticals business into Abbvie Inc., an independent, publicly traded company. Since that time the company has been a favorite with investors. Will the company be able to repeat that performance going forward?

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription